Northern Trust’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.2M Buy
184,852
+8,038
+5% +$627K ﹤0.01% 1879
2025
Q4
$14M Sell
176,814
-11,785
-6% -$1.02M ﹤0.01% 1902
2025
Q3
$17.3M Sell
188,599
-874
-0.5% -$71.3K ﹤0.01% 1790
2025
Q2
$12.4M Sell
189,473
-27,389
-13% -$1.78M ﹤0.01% 1940
2025
Q1
$14.5M Buy
216,862
+12,517
+6% +$748K ﹤0.01% 1821
2024
Q4
$11.3M Buy
204,345
+16,820
+9% +$966K ﹤0.01% 2056
2024
Q3
$11.2M Buy
187,525
+19,780
+12% +$1.21M ﹤0.01% 2005
2024
Q2
$10.7M Buy
167,745
+4,399
+3% +$286K ﹤0.01% 1958
2024
Q1
$11.3M Sell
163,346
-3,756
-2% -$227K ﹤0.01% 1962
2023
Q4
$9.21M Sell
167,102
-3,083
-2% -$170K ﹤0.01% 2128
2023
Q3
$9.88M Buy
170,185
+15,633
+10% +$902K ﹤0.01% 2016
2023
Q2
$8.32M Buy
154,552
+14,710
+11% +$652K ﹤0.01% 2195
2023
Q1
$5.55M Sell
139,842
-1,672
-1% -$70.5K ﹤0.01% 2397
2022
Q4
$5.69M Buy
141,514
+4,735
+3% +$178K ﹤0.01% 2406
2022
Q3
$4.4M Buy
136,779
+845
+0.6% +$28.9K ﹤0.01% 2567
2022
Q2
$4.03M Buy
135,934
+11,333
+9% +$327K ﹤0.01% 2642
2022
Q1
$3.5M Sell
124,601
-1,158
-0.9% -$43.2K ﹤0.01% 2787
2021
Q4
$5.79M Buy
125,759
+7,374
+6% +$317K ﹤0.01% 2599
2021
Q3
$3.88M Sell
118,385
-196
-0.2% -$6.09K ﹤0.01% 2893
2021
Q2
$4.16M Buy
118,581
+1,528
+1% +$52K ﹤0.01% 2961
2021
Q1
$4.23M Sell
117,053
-7,639
-6% -$239K ﹤0.01% 2855
2020
Q4
$3.62M Buy
124,692
+960
+0.8% +$27.5K ﹤0.01% 2862
2020
Q3
$3.49M Sell
123,732
-4,371
-3% -$130K ﹤0.01% 2752
2020
Q2
$4.14M Sell
128,103
-3,294
-3% -$118K ﹤0.01% 2630
2020
Q1
$5.35M Buy
131,397
+2,790
+2% +$148K ﹤0.01% 2269
2019
Q4
$7.93M Sell
128,607
-4,510
-3% -$299K ﹤0.01% 2326
2019
Q3
$9.7M Buy
133,117
+14,076
+12% +$1.05M ﹤0.01% 2164
2019
Q2
$9.79M Buy
119,041
+2,404
+2% +$171K ﹤0.01% 2168
2019
Q1
$8.23M Sell
116,637
-526
-0.4% -$30.9K ﹤0.01% 2274
2018
Q4
$5.27M Sell
117,163
-928
-0.8% -$48.6K ﹤0.01% 2468
2018
Q3
$6.68M Buy
118,091
+1,285
+1% +$78.6K ﹤0.01% 2514
2018
Q2
$7.8M Buy
116,806
+4,710
+4% +$294K ﹤0.01% 2430
2018
Q1
$6.53M Sell
112,096
-1,505
-1% -$95.5K ﹤0.01% 2429
2017
Q4
$7.32M Sell
113,601
-43
-0% -$2.67K ﹤0.01% 2378
2017
Q3
$5.96M Buy
113,644
+739
+0.7% +$35.2K ﹤0.01% 2522
2017
Q2
$5.29M Buy
112,905
+5,599
+5% +$270K ﹤0.01% 2601
2017
Q1
$5.31M Buy
107,306
+4,141
+4% +$233K ﹤0.01% 2529
2016
Q4
$6.25M Buy
103,165
+1,884
+2% +$115K ﹤0.01% 2402
2016
Q3
$6.72M Buy
101,281
+1,681
+2% +$105K ﹤0.01% 2331
2016
Q2
$5.56M Buy
99,600
+451
+0.5% +$21.9K ﹤0.01% 2386
2016
Q1
$3.34M Buy
99,149
+924
+0.9% +$31.3K ﹤0.01% 2671
2015
Q4
$4.43M Buy
98,225
+7,206
+8% +$310K ﹤0.01% 2531
2015
Q3
$3.6M Buy
91,019
+10,644
+13% +$606K ﹤0.01% 2667
2015
Q2
$4.99M Buy
80,375
+5,140
+7% +$306K ﹤0.01% 2518
2015
Q1
$4.71M Buy
75,235
+1,911
+3% +$116K ﹤0.01% 2540
2014
Q4
$4.13M Sell
73,324
-1,564
-2% -$69K ﹤0.01% 2632
2014
Q3
$2.12M Buy
74,888
+56,738
+313% +$1.7M ﹤0.01% 3063
2014
Q2
$625K Buy
18,150
+7,334
+68% +$230K ﹤0.01% 3540
2014
Q1
$339K Buy
10,816
+749
+7% +$19.9K ﹤0.01% 3650
2013
Q4
$202K Buy
+10,067
New +$131K ﹤0.01% 3715
2013
Q3
Sell
-6,352
Closed -$38K 4078
2013
Q2
$38K Buy
+6,352
New +$44.5K ﹤0.01% 3957

Other funds holding ANIP

Northern Trust's ANIP Position: Q1 2026 in Review

Northern Trust increased its ANI Pharmaceuticals (ANIP) stake by 4.5% in Q1 2026, buying an estimated $627K and bringing the position to 184,852 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1879.

Northern Trust first reported a position in ANIP in Q2 2013 and has held it in 51 quarters since. The position peaked at $17.3M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Northern Trust held 184,852 shares of ANI Pharmaceuticals worth $14.2M as of Q1 2026.
  • Northern Trust bought 8,038 ANI Pharmaceuticals shares in Q1 2026, an estimated $627K.
  • ANI Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1879 holding.
  • Northern Trust first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Northern Trust's ANI Pharmaceuticals position peaked at $17.3M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.